4/2
08:01 am
biib
Biogen (BIIB) had its price target raised by HC Wainwright from $228.00 to $237.00. They now have a "buy" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by HC Wainwright from $228.00 to $237.00. They now have a "buy" rating on the stock.
4/1
09:09 am
biib
Biogen (BIIB) had its price target raised by Wedbush from $187.00 to $191.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by Wedbush from $187.00 to $191.00. They now have a "neutral" rating on the stock.
4/1
09:09 am
biib
Biogen (BIIB) had its price target raised by Oppenheimer Holdings, Inc. from $250.00 to $275.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by Oppenheimer Holdings, Inc. from $250.00 to $275.00. They now have an "outperform" rating on the stock.
4/1
09:09 am
biib
Biogen (BIIB) had its price target raised by Canaccord Genuity Group Inc. from $230.00 to $245.00. They now have a "buy" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by Canaccord Genuity Group Inc. from $230.00 to $245.00. They now have a "buy" rating on the stock.
3/31
01:01 pm
biib
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio [Yahoo! Finance]
Low
Report
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio [Yahoo! Finance]
3/31
06:59 am
biib
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Low
Report
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
3/30
12:22 pm
biib
Biogen high-dose Spinraza approval seen supporting long-term growth [Yahoo! Finance]
Low
Report
Biogen high-dose Spinraza approval seen supporting long-term growth [Yahoo! Finance]
3/30
07:38 am
biib
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy [Yahoo! Finance]
Low
Report
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy [Yahoo! Finance]
3/30
07:30 am
biib
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Low
Report
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
3/28
03:19 pm
biib
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity [Yahoo! Finance]
Low
Report
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity [Yahoo! Finance]
3/28
03:00 pm
biib
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Low
Report
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
3/20
12:05 pm
biib
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Low
Report
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
3/19
08:00 am
biib
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action
Low
Report
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action
3/19
07:30 am
biib
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Low
Report
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
3/19
04:52 am
biib
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans [Yahoo! Finance]
Low
Report
Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans [Yahoo! Finance]
3/17
09:17 am
biib
Biogen (BIIB) had its price target raised by HSBC Holdings plc from $143.00 to $150.00.
Low
Report
Biogen (BIIB) had its price target raised by HSBC Holdings plc from $143.00 to $150.00.
3/13
02:27 am
biib
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]
Low
Report
Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]
3/11
05:28 pm
biib
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? [Yahoo! Finance]
Low
Report
Biogen Stock: Is BIIB Outperforming the Healthcare Sector? [Yahoo! Finance]
3/11
11:23 am
biib
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock [Yahoo! Finance]
Low
Report
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock [Yahoo! Finance]
3/11
08:03 am
biib
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy [Yahoo! Finance]
Low
Report
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy [Yahoo! Finance]
3/11
08:00 am
biib
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
Low
Report
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
3/10
06:18 am
biib
Aduhelm (Biogen, Eisai) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
Low
Report
Aduhelm (Biogen, Eisai) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
3/9
12:53 pm
biib
Navigating Postpartum Depression [Globe and Mail, The (Toronto, Canada)]
Low
Report
Navigating Postpartum Depression [Globe and Mail, The (Toronto, Canada)]
3/6
04:31 pm
biib
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts [Yahoo! Finance]
Low
Report
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts [Yahoo! Finance]
3/5
08:48 am
biib
What Makes Biogen (BIIB) an Attractive Long-Term Holding? [Yahoo! Finance]
Low
Report
What Makes Biogen (BIIB) an Attractive Long-Term Holding? [Yahoo! Finance]